- Home
- LMND vs DNLI Comparison
LMND vs DNLI Comparison
Compare LMND & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMND
- DNLI
- Stock Information
- Founded
- LMND 2015
- DNLI 2013
- Country
- LMND United States
- DNLI United States
- Employees
- LMND N/A
- DNLI N/A
- Industry
- LMND Property-Casualty Insurers
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LMND Finance
- DNLI Health Care
- Exchange
- LMND Nasdaq
- DNLI Nasdaq
- Market Cap
- LMND 2.0B
- DNLI 1.8B
- IPO Year
- LMND 2020
- DNLI 2017
- Fundamental
- Price
- LMND $26.78
- DNLI $12.74
- Analyst Decision
- LMND Hold
- DNLI Strong Buy
- Analyst Count
- LMND 9
- DNLI 16
- Target Price
- LMND $34.44
- DNLI $37.57
- AVG Volume (30 Days)
- LMND 1.8M
- DNLI 1.7M
- Earning Date
- LMND 04-29-2025
- DNLI 05-06-2025
- Dividend Yield
- LMND N/A
- DNLI N/A
- EPS Growth
- LMND N/A
- DNLI N/A
- EPS
- LMND N/A
- DNLI N/A
- Revenue
- LMND $526,500,000.00
- DNLI N/A
- Revenue This Year
- LMND $27.59
- DNLI N/A
- Revenue Next Year
- LMND $32.79
- DNLI $372.05
- P/E Ratio
- LMND N/A
- DNLI N/A
- Revenue Growth
- LMND 22.50
- DNLI N/A
- 52 Week Low
- LMND $14.03
- DNLI $10.57
- 52 Week High
- LMND $53.85
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- LMND 39.48
- DNLI 42.15
- Support Level
- LMND $26.08
- DNLI $12.37
- Resistance Level
- LMND $28.20
- DNLI $13.63
- Average True Range (ATR)
- LMND 2.58
- DNLI 1.24
- MACD
- LMND -0.23
- DNLI 0.23
- Stochastic Oscillator
- LMND 29.21
- DNLI 50.94
About LMND Lemonade Inc.
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.